Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
World Journal of Surgical Oncology
Published in: World Journal of Surgical Oncology 1/2014

Open Access 01-12-2014 | Case report

Goserelin plus endocrine treatments maintained long-term clinical benefit in a male patient with advanced breast cancer

Authors: Hang Jiang, Tao Wang, Zefei Jiang

Published in: World Journal of Surgical Oncology | Issue 1/2014

Login to get access

Abstract

Background

Goserelin plus aromatase inhibitors (AI) have already been used in male advanced breast cancer, but the cases that fulvestrantin male breast cancer are rare.

Case presentation

Here we report a case of long-term (3 years) response to Goserelin plus continuing endocrine treatments given for a male advanced breast cancer. The patient prolongs his life with high life quality, and has more time with his family.

Conclusion

Goserelin plus endocrine treatments may benefit male breast cancer.
Appendix
Available only for authorised users
Literature
1.
Johnston SJ, Cheung KL: Fulvestrant - a novel endocrine therapy for breast cancer [J]. Curr Med Chem. 2010, 17: 902-914. 10.2174/092986710790820633.CrossRefPubMed
2.
Antonis V, Davide M, Nikolaos P, Polyzos NP, Dimitris M, Vassilis G, Giovanni C: Fulvestrant in the treatment of advanced breast cancer: a systematic review and meta-analysis of randomized controlled trials [J]. Cr Rev Oncol-Hem. 2010, 73: 220-227. 10.1016/j.critrevonc.2009.03.006.CrossRef
3.
Masci G, Gandini C, Zuradelli M, Pedrazzoli P, Torrisi R, Lutman FR, Santoro A: Fulvestrant for advanced male breast cancer patients: a case series [J]. Ann Oncol. 2011, 22: 985-993. 10.1093/annonc/mdr005.CrossRefPubMed
Metadata
Title
Goserelin plus endocrine treatments maintained long-term clinical benefit in a male patient with advanced breast cancer
Authors
Hang Jiang
Tao Wang
Zefei Jiang
Publication date
01-12-2014
Publisher
BioMed Central
Published in
World Journal of Surgical Oncology / Issue 1/2014
Electronic ISSN: 1477-7819
DOI
https://doi.org/10.1186/1477-7819-12-393

Other articles of this Issue 1/2014

World Journal of Surgical Oncology 1/2014 Go to the issue

Case report

Inflammatory myofibroblastic tumor of the thigh without bone involvement: a case report

Research

Relationship between bladder cancer and total fluid intake: a meta-analysis of epidemiological evidence

Case report

Bile duct adenoma: a case report and literature review

Research

Red blood cell folate as a risk factor for breast cancer among patients at a tertiary hospital in Uganda: a case control study

Case report

Nasal chondromesenchymal hamartoma in young children: CT and MRI findings and review of the literature

Research

Correlation of histological components with tumor invasion in pulmonary adenocarcinoma